Home Biosimilar Antibodies Others Others Lirilumab (Anti-KIR)
For research use only. Not for use in humans.

Lirilumab (Anti-KIR)

Synonyms: CD158

Lirilumab (Anti-KIR) is a  fully human monoclonal antibody against killer-cell immunoglobulin-like receptors (KIR), with potential antineoplastic activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research. MW: 150 kD.

Lirilumab (Anti-KIR)

Quality Control

Batch: A241901 Purity: 99% Protein concentration: 5.665mg/ml Endotoxin Level: ＜1EU/mg
99

Mechanism of Action

Description
Lirilumab (Anti-KIR) is a  fully human monoclonal antibody against killer-cell immunoglobulin-like receptors (KIR), with potential antineoplastic activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research. MW: 150 kD.

Product Details

CAS No. 1000676-41-4
Molecular Weight 150 kDa
Isotype Human IgG4SP
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02813135 RECRUITING Drug: Ribociclib|Drug: Topotecan|Drug: Temozolomide|Drug: Ev Pediatric Cancer Gustave Roussy, Cancer Campus, Grand Paris 2016-08-03 PHASE1; PHASE2
NCT03341936 ACTIVE_NOT_RECRUITING Drug: Nivolumab|Drug: Lirilumab Squamous Cell Carcinoma of the Head and Neck Dana-Farber Cancer Institute 2018-03-15 PHASE2
NCT03347123 TERMINATED Drug: Epacadostat|Drug: Nivolumab|Drug: Ipilimumab|Drug: Lir Solid Tumors Incyte Corporation 2018-03-21 PHASE1; PHASE2
NCT03532451 COMPLETED Drug: Nivolumab|Drug: Nivolumab/Lirilumab Bladder Cancer PrECOG, LLC. 2019-03-22 PHASE1
NCT01592370 COMPLETED Drug: Pomalidomide|Drug: Dexamethasone Non-Hodgkin's Lymphoma; Hodgkin Lymphoma; Multiple Myeloma Bristol-Myers Squibb 2012-08-02 PHASE1; PHASE2
NCT03203876 COMPLETED Advanced Cancer Bristol-Myers Squibb 2017-07-14 PHASE1

(data from https://clinicaltrials.gov, updated on 2026-07-10)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.